Search
Alprazolam
go.drugbank.com/drugs/DB00404ApprovedIllicitInvestigational[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148] … [A18125] Alprazolam's adverse effects are generally related to the sedation it can cause.
Products: Alprazolam ER, ALPRAZOLAM EGMethotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients … [L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198]
Synonyms: 4-amino-N(10)-methylpteroylglutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acidProducts: NORDIMET 10MG ILO I E FER, NORDIMET 15MG ILO I E FEROxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigationalIt is often used as first-line therapy for OAB.[A185990] … efficacy since initial FDA approval in 1975.
Products: OXIBUTININA EG, Pat-oxybutynin Chloride ERTizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalIt may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. … Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons
Products: SIRDALUD 2MG, TIZANIDIN TEVA 2MG TABLRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.
Products: Jakavi 15mg Tablets, Jakavi 10mg TabletsDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: DARUCIL® ER 15 MG, EMSELEX 15MG RETDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalbinding at the ATP domain of the epidermal growth factor receptor family kinase domains. … [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed.
Products: VIZIMPRO FILM-COATED TABLET 15MG, Vizimpro 30 mg Film-Coated TabletsDarbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Products: ARANESP® 100µG SOLUCION INYECTABLE EN JERINGA PRELLENADA, ARANESP® 50 MCG SOLUCIÓN INYECTABLE EN JERINGA PRELLENADALovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A174553] More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid … [A181087, A181406] Lovastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line
Products: LOVASTATINA EG, LOVAHEXAL 10MG TABLMidodrine
go.drugbank.com/drugs/DB00211ApprovedInvestigationalAn ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.
Synonyms: (±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide, 2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamideProducts: MIDODRINA EG, Miron 10mg Tablets